| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.046 | 0.2 |
| mRNA | ABT-737 | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | MG-132 | GDSC1000 | pan-cancer | AAC | 0.062 | 0.2 |
| mRNA | AZD1480 | CTRPv2 | pan-cancer | AAC | -0.069 | 0.2 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | Dasatinib | FIMM | pan-cancer | AAC | -0.2 | 0.2 |
| mRNA | GSK690693 | GDSC1000 | pan-cancer | AAC | 0.039 | 0.2 |
| mRNA | BRD-K71781559 | CTRPv2 | pan-cancer | AAC | -0.049 | 0.2 |